IP Library Granted Patent US 7,087,227
Granted Patent B2
US 7,087,227 · App. 10/413,000 · Granted Aug 8, 2006

Cartilage composites and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,087,227
App. No.
10/413,000
Granted
Aug 8, 2006
Kind
B2
Abstract

Disclosed are neocartilage compositions characterized by having multiple layers of cells, said cells being surrounded by a substantially continuous insoluble glycosaminoglycan and collagen-enriched hyaline extra-cellular matrix, and which neocartilage phospholipids are advantageously enriched in anti-inflammatory n-9 fatty acids, particularly 20:3 n-9 eicosatrienoic or Mead acid. Also disclosed are methods of growing neocartilage in substantially serum-free growth media and methods of producing a conditioned growth media containing compounds effective to enhance neocartilage formation. The neocartilage compositions are useful as implants and as replacement tissue for damaged or defective cartilage and as a model system for studying articular cartilage disease and response to natural and synthetic compounds.

Claims (13)

1. An ex vivo composite comprising multiple layers of chondrocytes enriched in high molecular weight aggrecan and surrounded by a substantially continuous insoluble hyaline extracellular matrix affixed to a noncartilaginous biocompatible material.

2. A composite as set forth in claim 1 wherein the chondrocytes further comprise linoleic acid-depleted membrane phospholipids.

3. A composite as set forth in claim 1 wherein the chondrocytes further comprise arachidonic acid-depleted membrane phospholipids.

4. A composite as set forth in claim 1 wherein the chondrocytes further comprise Mead acid-enriched membrane phospholipids.

5. A composite as set forth in claim 1 wherein the chondrocytes are mammalian or avian chondrocytes.

6. A composite as set forth in claim 5 wherein the chondrocytes are human chondrocytes.

7. A composite as set forth in claim 1 wherein the biocompatible material comprises bone allogeneic to an intended recipient of the composite.

8. A composite as set forth in claim 1 wherein the biocompatible material comprises bone xenogeneic to an intended recipient of the composite.

9. A composite as set forth in claim 1 wherein the biocompatible material comprises demineralized bone.

10. A composite as set forth in claim 1 wherein the biocompatible material comprises a biosynthetic polymer.

11. A composite as set forth in claim 1 wherein the chondrocytes are immature chondrocytes.

12. A kit comprising an implant containing a reparative amount of the composite of claim 1 and means for implanting and adhering the composite in a target tissue locus.

13. A method for repair or replacement of a cartilage or bone and cartilage defect in a subject comprising surgically implanting and adhering the composite of claim 1 .

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jun 7, 2016
From: MIDCAP FUNDING XVIII TRUST, AS SUCCESSOR IN INTEREST TO MIDCAP FINANCIAL SBIC, LP
To: ISTO TECHNOLOGIES, INC.
Reel/Frame 038903/0645 →
SECURITY INTEREST Recorded Jan 23, 2015
From: ISTO TECHNOLOGIES, INC.
To: MIDCAP FINANCIAL SBIC, LP
Reel/Frame 034805/0001 →
INTELLECTUAL PROPERTY COVENANT NOT TO SUE AGREEMENT Recorded Mar 14, 2013
From: ISTO TECHNOLOGIES, INC.
To: ZIMMER, INC.
Reel/Frame 029993/0019 →